15-type HPV Genotyping
15-type HPV Genotyping

[Product Name]

Human Papillomavirus (HPV) Nucleic Acid Typing Detection Kit 2.1

15-type HPV Genotyping CHE-HPV15-201

[Packing Specifications]

12 tests / box

[Applicable Models]

Flex-Disc (Model: CH-0104) Fully Automated Nucleic Acid Analyzer

[Download Brochure]

15-type HPV GenotypingChenghui-Flex-Disc-15-Human-Papillomavirus-HPV-Nucleic-Acid-Typing-Detection-Kit-Brochure.pdf


No Data

Testing Process

No Data

Intended Use


This kit is a multiplex nucleic acid test intended for the qualitative detection and identification of Human Papillomavirus (HPV) types 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, and 68 nucleic acid DNA in female cervical exfoliated cell samples.

Challenges


Persistent infection with high-risk Human Papillomavirus (HPV) is the primary cause of cervical cancer, and widespread standardized screening is the core strategy for cervical cancer prevention and control. For hospital outpatient departments, primary care clinics, community health centers and public health screening systems, conventional HPV diagnostic approaches have four core unmet needs:


Suboptimal screening accuracy with limited risk stratification capacity

Cytology-based tests such as Pap smears have relatively low sensitivity and high false-negative rates, leading to missed diagnoses. Most basic HPV assays only distinguish high-risk from low-risk types without precise genotyping, making it impossible to stratify patients with high-carcinogenic genotypes such as HPV 16 and 18. This often results in over-treatment or insufficient clinical intervention, especially in grassroots settings with limited specialist resources.


Long centralized testing turnaround reduces patient follow-up compliance

Traditional HPV nucleic acid testing relies on centralized molecular laboratories, with complex sample transfer and batch processing workflows that take 3–7 days to issue reports. Patients are required to make multiple return visits, leading to high loss-to-follow-up rates and delayed clinical intervention. For grassroots screening programs, long-distance sample transport also increases costs and risks of sample degradation.


High operational barriers limit deployment in primary care and screening sites

Conventional nucleic acid testing requires standardized PCR laboratories and certified technical personnel, conditions that are largely unavailable in community health centers, township maternal and child health stations and remote medical sites. This greatly limits the accessibility of precise HPV genotyping and restricts the coverage of population-level cervical cancer screening.


Inflexible throughput fails to match fluctuating screening demand

Primary care facilities typically have low daily testing volumes, making high-throughput PCR instruments cost-inefficient due to long idle periods. During large-scale public health screening campaigns, however, sample volumes surge sharply. There is a lack of elastically scalable testing solutions, and cold chain reliance further restricts large-scale deployment in grassroots and remote areas.


Core Benefits


The Human Papillomavirus (HPV) Nucleic Acid Typing Detection Kit (15 targets), paired with the Flex-Disc fully automated nucleic acid analysis platform, directly addresses the above outpatient and primary care pain points:


15-type HPV GenotypingPrecise 15-genotype profiling to support standardized clinical decision-making

A single run achieves qualitative detection and genotyping of 15 high-risk HPV genotypes recognized by the WHO, including the highest-risk HPV 16 and 18. It provides clear evidence for clinical risk stratification, colposcopy referral and post-treatment follow-up, standardizing cervical cancer diagnosis and management pathways even in primary care settings.


Results in around 40 minutes to improve care efficiency and patient compliance

Total testing time is around 40 minutes, with only 1 minute of hands-on sample loading. Full genotyping reports are available within a single outpatient visit, eliminating the need for repeated patient return trips and improving follow-up compliance. It also supports same-day reporting for physical examinations and on-site screening, greatly improving clinical and public health operational efficiency.


Low-barrier POCT deployment to expand screening accessibility

Powered by the fully automated closed Flex-Disc platform, the assay requires no standardized molecular laboratory or specialized technical staff, and can be operated by frontline medical workers after brief training. It can be deployed directly in gynecology outpatient departments, community health centers, grassroots maternal and child health facilities and physical examination centers, bringing precise HPV genotyping testing to underserved settings and expanding cervical cancer screening coverage.


Modular scalable throughput to adapt to diverse scenario needs

Each independent Flex-Disc testing module processes one sample at a time, with a single control terminal supporting wireless connection to up to 8 modules simultaneously. Facilities can scale the number of modules according to actual sample volume: a single module meets routine outpatient demand, while multi-module parallel operation handles large-scale public health screening campaigns, balancing operational cost and testing capacity.


Core Product Advantages


Guideline-aligned 15 high-risk genotype panel for primary care scenarios

The panel covers 15 globally recognized high-risk and probable high-risk HPV genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68), fully consistent with international cervical cancer screening and management guidelines. It meets the needs of routine outpatient screening, high-risk patient management and post-operative follow-up, with an optimal balance of comprehensiveness and cost-effectiveness for primary care.


Fully automated closed sample-to-result workflow

Leveraging proprietary centrifugal microfluidic technology, the kit integrates two gold-standard workflows — silica membrane-based nucleic acid extraction and multiplex real-time qPCR — within a single enclosed disposable cartridge. Only 1 minute of manual pipetting is required, with no professional molecular operation expertise needed, delivering true load-and-go detection.


Modular scalable throughput design for flexible deployment

Compatible with the Flex-Disc (Model: CH-0104) Fully Automated Nucleic Acid Analyzer, each testing module processes 1 sample per run with full genotyping results available in around 40 minutes. One main control terminal can connect wirelessly to up to 8 testing modules, supporting random access and parallel testing to flexibly match sample volumes from small primary clinics to large-scale public health screening programs.

15-type HPV Genotyping

Lyophilized reagents for room-temperature storage and transport

With our self-developed PCR reagent lyophilization process, pre-embedded lyophilized reagent beads in the microfluidic chip enable room-temperature storage and transportation, eliminating cold chain reliance. This greatly reduces storage and logistics costs for primary care facilities and remote screening sites, supporting large-scale public health deployment.


Zero cross-contamination closed cartridge system

Each sample is processed in an individual sealed disposable cartridge, with amplification products never exposed to the external environment. This design fundamentally eliminates aerosol cross-contamination, reduces on-site quality control requirements, and ensures stable, reliable results even in non-laboratory primary care settings.


CE-compliant with clinically validated sample compatibility

The assay is fully validated for female cervical exfoliated cell samples. All 15 HPV genotyping targets are CE-marked, meeting regulatory requirements for clinical outpatient diagnosis and public health cervical cancer screening across global primary care markets.